Entrada Therapeutics, Inc. (TRDA)
- Sector
- Biotechnology
- Last price
- $4.96
- As of
Kresmion compiles this page from TRDA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Entrada Therapeutics, Inc. (TRDA): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-05.
See the full TRDA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TRDA on one page. Preview it with sample data, then open it live with a free account.
Preview the TRDA dossierActive events for TRDA
- mediumEarnings above estimates
Q3-2026: Beat consensus by 9.0%, EPS $-0.94 vs $-1.0331 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +120% to TRDA (2026Q2)
- high13F: large reduction
D. E. Shaw & Co., Inc. cut 59% of TRDA (2026Q2)
- mediumEarnings above estimates
Q2-2026: Beat consensus by 5.7%, EPS $-1.01 vs $-1.071 estimate
- mediumEarnings above estimates
Q4-2025: Beat consensus by 19.9% - EPS $-0.94 vs $-1.173 estimate
FREE, NO ACCOUNT
Every event on TRDA, as it fires
You are seeing 5 of 9 events recorded on TRDA since 2026-05-24.
The five above landed across 4 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
TRDA positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 29384C108 · 2026Q3 | $1.3M | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TRDA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
TRDA's 10-Q filed Nov 5, 2026 states:
We have identified conditions that raise substantial doubt about our ability to continue as a going concern.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on TRDA
TRDA against its peers
TRDA's operating margin of -621.1% ranks in the 37th percentile of 14 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | TRDA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 25.4M USD | 12.0M USD | 77 | 14 |
| Revenue YoY | n/a | -16.0% | n/a | 6 |
| Gross margin | n/a | 82.8% | n/a | 7 |
| Operating margin | -621.1% | -262.4% | 37 | 14 |
| Net margin | -565.5% | -288.3% | 41 | 15 |
| Return on equity | -47.0% | -56.3% | 57 | 21 |
| 1 year | -45.5% | -7.1% | 23 | 23 |
Peers (23): PRQR, CGEN, ARTV, PALI, NGEN, RNAC, PYXS, ACIU, KRRO, IKT, MDWD, PROK, GLSI, WHWK, SLGL, KROS, ANIK, ELDN, ANTX, ACOG, LCTX, IFRX, BBOT. Left out: HSTC (period gap), DRUG (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (TRDA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in TRDA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on TRDA in the last 180 days.
Upstream: SEC EDGAR filings for TRDA
Kresmion, "Entrada Therapeutics, Inc. (TRDA) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/TRDA. Upstream data: SEC EDGAR filings for TRDA.
Link to this data (HTML):
<a href="https://kresmion.com/research/TRDA">Entrada Therapeutics, Inc. (TRDA) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow TRDA on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to TRDA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.